SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Immunome Says EMA Validated Varegacestat Marketing Application

Immunome said its marketing authorization application for varegacestat to treat adults with desmoid tumors has been validated by the EMA. The application is supported by positive Phase 3 RINGSIDE results.

IMNM

Story updates

11:30:17 AM UTC
SquawkNews
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an inve…

Related stories